CSI Market
Sign In | Register

Immunoprecise Antibodies Ltd (IPA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access IPA Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Immunoprecise Antibodies Ltd adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jan 31 2026)
9 Months 		(Oct 31 2025) (Jul 31 2025) (Apr 30 2025) (Jan 31 2025)
Operating Activities
Income-8.19
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Adjustments For Unrealised Foreign Exchange Losses Gains0.26
Adjustments For Accretion Expense-
Adjustments For Depreciation And Amortisation Expense-
Adjustments For Sharebased Payments-
Cash Flows From Used In Operations Before Changes In Working Capital-
Adjustments For Decrease Increase In Unbilled Revenue-
Adjustments For Decrease Increase In Prepaid Expenses-
Adjustments For Increase Decrease In Trade And Other Payables-
Adjustments For Increase Decrease In Taxes Payable And Receivable-
Adjustments For Increase Decrease In Deferred Income Including Contract Liabilities-
Income taxes0.00
Adjustments For Gains Losses On Fair Value Adjustment Investment Property0.00
Accounts Receivable0.00
Adjustments For Decrease IncreaseIn Trade Account Receivable-0.67
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.33
Discontinued operations0.00
Net Cash flow from Operating Activities-7.27
Investing Activities
Capital Expenditures0.28
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Security Deposit On Leases-
Purchase Of Other Longterm Assets Classified As Investing Activities-
Purchase Of Customer List Classified As Investing Activities-
Deferred Acquisition Payment Investing Activities-
Other Cash Receipts From Sales Of Equity Or Debt Instruments Of Other Entities Classified As Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.36
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-10.45
Discontinued operations0.00
Net Cash Flow from Investing Activities-9.80
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.29
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.29
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-6.99
Total Cash Flow0.00
4 historic quarters locked

Sign in to unlock the full Immunoprecise Antibodies Ltd cash flow history.

Sign In Create Free Account

About Mindwalk Holdings Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-312694

Figures are derived from filed reports and may be restated. Historical data is subject to revision.